Pharmaceuticals

SUNHERE

SUNHERE released FY2026 Q1 earnings on April 22 Pre-Market (BJT), actual revenue CNY 261.39 M, actual EPS CNY 0.19

SUNHERE released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 246.29 M, actual EPS CNY 0.18

SUNHERE released FY2025 annual earnings on April 22 After-Market (BJT), actual revenue CNY 942.8 M (forecast CNY 998 M), actual EPS CNY 0.73 (forecast CNY 0.79)

SUNHERE to release FY2025 earnings report on April 23 After-Market BJT, forecast revenue CNY 998 M, EPS CNY 0.79

SUNHERE to Release FY2026 Q1 Earnings Report on April 23 Pre-Market BJT

Fosun Pharmaceutical Plans to Reduce Holdings in Shanhe Pharmaceutical Auxiliaries

SUNHERE released FY2025 Q3 earnings on October 20 Pre-Market (BJT), actual revenue CNY 225.66 M, actual EPS CNY 0.1693

SUNHERE released FY2025 9 Months Earnings on October 20 Pre-Market (BJT), actual revenue CNY 696.5 M, actual EPS CNY 0.5493

SUNHERE to Release FY2025 Q3 Earnings on October 21 Pre-Market BJT

SUNHERE released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue CNY 222.97 M, actual EPS CNY 0.1899

SUNHERE released FY2025 Semi-Annual Earnings on August 26 After-Market (BJT), actual revenue CNY 470.84 M, actual EPS CNY 0.38

SUNHERE FY2025 Semi-Annual Earnings Release on August 27, 2025 (BJT)

Shanhe Pharmaceutical Auxiliary Obtained Registration Number for Mannitol Pellets from CDE

Shanhe Pharmaceutical Auxiliary's Shareholder Completed Share Reduction Plan

Fosun Pharmaceutical Completes Reduction Plan for Shanhe Pharmaceutical Auxiliary Shares

Shanhe Pharmaceutical Auxiliary Responds to Impact of Sino-US Trade Friction

Shanheyaofu's Revenue Increases 4.28% in Q1 2025

Shanhe Pharmaceutical Auxiliary Reports a Decline in Net Profit in 2024 and Plans to Distribute 3 Yuan in Cash Dividends per 10 Shares

SUNHERE released FY2024 annual earnings on April 22 After-Market (BJT), actual revenue CNY 882.57 M (forecast CNY 945 M), actual EPS CNY 0.51 (forecast CNY 0.79)

SUNHERE released FY2024 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 238.22 M, actual EPS CNY -0.013

300452

600196

02196

According to the announcement from Dolphin Research, SUNHERE announced that its shareholder Shanghai FOSUN PHARMA Industrial Development Co., Ltd. (hereinafter referred to as "FOSUN PHARMA") intends to reduce its holdings of the company's shares by no more than 6.9787 million shares, or no more than 3% of the company's total share capital, through centralized bidding and block trading within 90 days after 15 trading days from the date of the announcement (from November 24, 2025, to February 21, 2026)

Zhitong

FOSUN PHARMA

SUNHERE's shareholder FOSUN PHARMA plans to reduce its holdings by no more than 3%

According to the Zhitong Finance APP, SUNHERE released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 697 million yuan, a year-on-year increase of 8.09%. The net profit attributable to shareholders of the listed company was 133 million yuan, a year-on-year increase of 8.28%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 120 million yuan, a year-on-year increase of 14.02%. The basic earnings per share were 0.57 yuan

SUNHERE released its performance for the first three quarters, with a net profit attributable to the parent company of 133 million yuan, an increase of 8.28%

SUNHERE announced that the controlling shareholder and actual controller has changed from Yin Zhenglong to Wu Changhong. After the passing of Yin Zhenglong, his wife Wu Changhong and daughter Yin Zhiya inherited the company's shares. Wu Changhong directly holds 20.172% of the shares, while Yin Zhiya holds 6.724% of the shares and has signed a "Voting Rights Delegation Agreement," entrusting all identity rights of her shares to Wu Changhong for exercise

SUNHERE: The controlling shareholder and actual controller has changed from Yin Zhenglong to Wu Changhong

According to the Zhitong Finance APP, SUNHERE released its semi-annual report for 2025, showing that the company's operating income was 471 million yuan, an increase of 4.65% year-on-year. The net profit attributable to shareholders of the listed company was 93.0352 million yuan, a decrease of 2.61% year-on-year. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 84.754 million yuan, an increase of 6.05% year-on-year. The basic earnings per share were 0.4 yuan

SUNHERE released its performance for the first half of the year, with a net profit attributable to the parent company of 93.0352 million yuan, a decrease of 2.61%

According to the Zhitong Finance APP, SUNHERE announced that the company has added a new pharmaceutical excipient product: Mannitol pellet core has obtained the registration number from the National Medical Products Administration's Center for Drug Evaluation (referred to as "CDE"), which is F20250000241. Mannitol pellet core is a white or off-white spherical pellet made from D-mannitol and other excipients, primarily used as a carrier for enteric-coated micro-pellet formulations and sustained-release micro-pellet formulations, and can also be used directly as a drug micro-pellet

SUNHERE has added 1 new pharmaceutical excipient product

603669

The chemical pharmaceutical sector continues to rise, with SUNHERE and Lionco hitting the daily limit, while Beilu Pharmaceutical, Hanyu Pharmaceutical, Yong'an Pharmaceutical, Xinghao Pharmaceutical, and Hasenlian also follow suit

Lionco

Beilu Pharma

HYBIO

YONGAN PHARMACEUTICAL

MEDISAN

The chemical pharmaceutical sector continues to rise, with SUNHERE and Lionco hitting the daily limit

SUNHERE announced that FOSUN PHARMA reduced its stake in the company by 0.98%. The reduction plan is expected to be completed by June 15, 2025, with an average reduction price of 12.54 yuan and a total of 2.2828 million shares reduced. After the reduction, FOSUN PHARMA holds 21.6453 million shares, accounting for 9.23% of the total share capital. This reduction does not violate any laws or regulations, and the company's operations are normal, with no change in control

SUNHERE: FOSUN PHARMA reduced its stake by 0.98%

002422

000963

002653

The concept stocks of generic drugs have pulled back, with KELUN PHARMA down over 5%, HUADONG MEDICINE, Haisco, and SUNHERE down over 4%

KELUN PHARMA

HUADONG MEDICINE

Haisco

SUNHERE released its 2024 annual report, with operating revenue of 883 million yuan, a year-on-year increase of 5.16%; net profit attributable to shareholders of the parent company was 119 million yuan, a year-on-year decrease of 26.07%; net profit excluding non-recurring gains and losses was 101 million yuan, a year-on-year decrease of 26.45%. The basic earnings per share were 0.51 yuan, and it plans to distribute a cash dividend of 3.00 yuan (including tax) for every 10 shares to all shareholders

SUNHERE released its 2024 annual performance, with a net profit attributable to the parent company of 119 million yuan, a year-on-year decrease of 26.07%

SUNHERE announced that its revenue for the first quarter of 2025 was 248 million yuan, a year-on-year increase of 4.28%; net profit was 47.1769 million yuan, a year-on-year decrease of 5.30%

SUNHERE: Net profit in the first quarter of 2025 was 47.1769 million yuan, a year-on-year decrease of 5.30%

SUNHERE(300452.SZ)